Adimab Inc., a Lebanon, N.H.-based developer of a human antibody discovery platform in yeast, has raised $8.2 million in Series D funding, according to a regulatory filing. The company announced the investment last week, but without a dollar amount.
Google Ventures led the round, and was joined by return backers OrbiMed Advisors, Borealis Ventures, Polaris Venture Partners and SV Life Sciences.
Adimab previously raised around $13.5 million. www.adimab.com
